FDA approves first treatment for breast cancer with a certain inherited genetic mutation

Posted on


  1. FDA approves first treatment for breast cancer with a certain inherited genetic mutation  FDA.gov
  2. Breast cancer survival ‘unaffected by faulty gene’  BBC News
  3. US OKs 1st drug aimed at women with inherited breast cancer  ABC News
  4. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study – The Lancet …  The Lancet
  5. Breast Cancer News, Research Center | Breast Cancer Articles – Cancer Therapy Advisor  Cancer Therapy Advisor
  6. Full coverage



Lynparza was first approved by the FDA in to treat certain patients with ovarian cancer and is now indicated for the treatment of patients with germline breast cancer susceptibility gene BRCA mutated, human epidermal growth factor receptor HER negative metastatic breast cancer, who have been previously . FDA approves first treatment for breast cancer with a certain inherited genetic mutation tumors have a specific inherited germline genetic mutation, making it the first drug in its class PARP inhibitor approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients .Days ago Olaparib, a PARP inhibitor, was first approved by FDA in to treat certain patients with ovarian cancer and is now indicated for the treatment of patients with germline breast cancer susceptibility gene BRCA mutated, human epidermal growth factor receptor HER negative metastatic breast cancer, who have been . Lynparza olaparib, AstraZeneca is now approved to treat patients with metastasized breast cancer and a BRCA mutation. This approval marks the first drug indicated to treat patients with a certain inherited genetic mutation. The FDA first approved Lynparza in to treat certain patients with ovarian .







Leave a Reply

Your email address will not be published. Required fields are marked *